hal.inserm.fr
hal.inserm.fr
CD200: a putative therapeutic target in cancer.
author(s): Jérôme Moreaux1, 2, Jean Luc Veyrune1, 2, Thierry Reme1, 2, John De Vos1, 2, Bernard Klein () 1, 2
laboratory:
1: IRB - Institut de recherche en biothérapie
CHRU Montpellier – Université Montpellier I
Hôpital Saint-Eloi 34000 Montpellier
France
2: Biothérapie des cellules souches normales et cancéreuses
INSERM : U847 – Institut de recherche en biothérapie – Université Montpellier I – CHRU Montpellier
Centre de recherche Inserm 99, rue puech villa 34197 MONTPELLIER CEDEX 5
France
abstract: CD200 was recently described as a new prognosis factor in multiple myeloma and acute myeloid leukemia. CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. We investigated the expression of CD200 in cancer using publicly available gene expression data. CD200 gene expression in normal or malignant human tissues or cell lines was obtained from the Oncomine Cancer Microarray database, Amazonia database and the ITTACA database. We found significant overexpression of CD200 in renal carcinoma, head and neck carcinoma, testicular cancer, malignant mesothelioma, colon carcinoma, MGUS/smoldering myeloma, and in chronic lymphocytic leukemia compared to their normal cells or their tissue counterparts. Moreover, we show that CD200 expression is associated with tumor progression in various cancers. Taken together, these data suggest that CD200 is a potential therapeutic target and prognostic factor for a large array of malignancies. |
